Nestl may shuck peanut allergy drug at center of $2.6 billion acquisition

San Francisco Business Journal

Nov 30, 2022

The food giant saw Aimmune as a potential $1 billion food allergy brand, but the rollout of the peanut allergy drug was hurt in part by Covid-19 restrictions. |!| San Francisco